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Background: Carcinoma of the Prostate is a major health burden globally. This study was 
aimed at assessing the value of digital rectal examination and prostate specific antigen as 
screening and diagnostic tools for carcinoma of the prostate in rural Nigeria 
Methods: Men who had abnormal digital rectal examination (DRE) findings, elevated 
prostate specific antigen (PSA) and prostatic histology within the period were included in 
the study. Data related to age, PSA value, DRE findings and histology were analyzed using 
SPSS and simple statistical methods. 
Result: The total number of patients was one hundred and fifty eight. The peak decade of 
occurrence of prostate cancer was the 61-70 years. When DRE findings was cross tabulated 
with histology, there was a significant correlation (P=.000). The positive predictive value 
(PPV) of DRE was 96.15% while the negative predictive value (NPV) was 93.5%. For PSA, 
there was also a significant correlation (P=.000). The PPV of PSA was 64.9% while the NPV 
was 96.33%. 
Conclusion: The extremely impressive performance of DRE and PSA as diagnostic and 
screening tools may be due to the limitation of the study to a cohort of patients who already 
hard lower urinary tract symptoms. There is need for community based studies. 
 




 Carcinoma of the Prostate Continues to be a major health burden worldwide1. According to 
Jason et al2, the life time prevalence of the disease is 17 percent. In the United States of 
American, 218, 890 diagnosis of the carcinoma of the prostate were expected in 2007 with 
corresponding deaths of 27,050. In most third world countries, such information are either 
scanty or nonexistent. In Nigeria, available information are from the Urban centers and are 
mostly on incidence of the disease; Port-Harcourt3 114/100,000, Lagos4 127/100,000. 
 
The diagnosis of Carcinoma of the prostate when affected men present for evaluation, is based 
on history, physical examination and Investigation. In simple uncomplicated disease, the history 
is similar to that of benign prostatic hyperplasia (BPH), consisting essentially of Lower Urinary 
Tract Symptoms (LUTS)5. In advanced disease when there are metastases,   additional 
symptoms present depend on the involved system. The hallmark of physical examination in 
carcinoma of the prostate is the digital rectal examination (DRE). Features on DRE which point 
to the presence of carcinoma of the prostate include enlarged prostate, lobar asymmetry, 
nodularity, suspicious nodules and a rubbery or hard prostate6. Argen et al7 in a systematic 
review concluded that DRE is the oldest least invasive screening tool for Ca prostate with a high 
specificity and a high negative predictive value though its moderate sensitivity does not allow 
for conclusion. An abnormal DRE finding is an indication for biopsy of the prostate. 
 
Prostate specific antigen (PSA), a protein serease produced only by the prostate, replaced acid 
phosphatase in 1986 as an investigating modality and has since become a reliable tumor marker 
and screening tool for carcinoma of the prostate8. PSA is not specific for carcinoma of the 
prostate as other diseases of the prostate such as BPH and prostatitis may lead to an elevated 
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value. PSA is also considered a tumor marker that is not sensitive enough as it is normal in some 
patients with prostate cancer.9 The universally accepted normal upper limit is 4ng/ml but it is 
also well know that at this upper limit of normal, some cancers are missed. Essentially, biopsy of 
the prostate is advised when the PSA value exceeds this upper limit. In order to improve the 
sensitivity of PSA, concepts such as age cut off, PSA velocity, free PSA and complex PSA were 
developed. 
 
PSA is presently the most reliable tumor marker in carcinoma of the prostate with a higher 
predictive value than DRE and TRUS.9 Available data indicate that the PSA level is as, or more 
effective than DRE for the detection of prostate carcinoma. Currently, for screening purpose, a 
combination of DRE and PSA is recommended as this approach yields up to 75% diagnostic 
sensitivity for prostate carcinoma though, in the American Cancer Society updated screening 
guidelines for prostate cancer, DRE is optional10. 
 
This study was done in Irrua Teaching Hospital, a Nigeria tertiary institution based in a semi 
urban setting and sub serving a population of 4 million people. To the best of our knowledge, 
the role of DRE and PSA in screening for prostate cancer has not been studied or documented in 
the rural Nigeria men. We therefore aim to add to available information on Ca prostate with 
particular reference to rural black Nigerian men. This study will assess the value of DRE and 
PSA as diagnostic and screening tools for Ca prostate in this group. 
 
Patients and Methods 
All men who presented at the Urology out patient, General outpatient and the Accident and 
Emergency unit of the hospital with LUTS BPH were included. However patients who were on 
treatment or have had treatment for prostatic disease before presentation at our hospital were 
exclude. Others excluded were LUTS due to Bladder diseases and Urethral stricture. All these 
men were assessed with DRE and PSA and those who's PSA exceeded 4ng/ml or had abnormal 
DRE findings were subjected to prostate biopsy. 
 
Digital rectal examination (DRE) was done in the left lateral position. In very sick patients, the 
supine position was used while the knee-elbow position was preferred in men who presented 
with urinary retention though the DRE was repeated after the retention had been relieved. 
Factors such as obliteration of the median groove, presence of suspicions nodules, lobar 
asymmetry, generalized nodularity, tenderness and palpability of the seminal vesicles were 
assessed for .All the DRE were done by specialist Urologists. 
 
The specimen for PSA measurement was obtained either before or at least fourty eight hours 
after the DRE. The specimen were centrifuged at three thousand revolutions per minute. The 
supernatant was stored at -2OC-8OC if the investigation was not done immediately. The DRG 
international Inc., USA enzyme-linked immunosorbent assay was generally used by this Center 
during the study period. The findings on DRE, PSA value, the histology report and patients age 
were recorded. The data so obtained was analyzed using the statistical programming for social 
sciences (SPSS-17) and simple statistical methods. Pearson chi square was used to compare age, 
DRE, PSA and histology. 
 
Results 
 A total of One hundred and Fifty -Eight patients seen within the study period with complete 
data suitable for this study were included. The age distribution is shown in Table 1. Of these, 95 
(60.1%) had CAP, 5 (3.2 %) had prostate intra-epithelial neoplasia and 58 (36.75%) had BPH on 
histological evaluation.  The peak age at diagnosis of both BPH and CAP was the seventh decade 
of life amounting to 35.4% of the total.  The minimum age at which the diagnoses of CAP and 
BPH were made was within the 5th decade of life (1.9%). 
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Table 1.  Age distribution of Patients 

















 Of the 158 patients, 62 (39.2%) had a benign feel of the prostate on DRE, 24 (15.2%) had an 
obliterated median groove, 13 (8.2%) had a suspicious nodule, 53 (33.5%) had a hard and 
nodular prostate and 6 (3.8%) had asymmetrical lobes giving a total malignant feel of the 
prostate of 96 (60.8%).  When DRE was cross examined against histology, a significant 
correlation was found (P = 0.000).  Eighty (84.21%) of the ninety six patients who had a 
malignant prostate on DRE had a histologically confirmed CAP, while 43 (68.25%) of these who 
had a benign finding on DRE were confirmed to have BPH. When age was cross tabulated with 
histology, there was no significant correlation (P= 0.431). The positive predictive value (PPV) of 
DRE was 96.15% while the negative predictive value (NPV) was 93.5%. 
 
Table 2 shows the PSA distribution side by side the findings when PSA is cross-tabulated with 
histology.  All the patients who's PSA were above 100ng/ml were histologically confirmed as 
having CAP.  Below this PSA value, a variable number of patients had histologically confirmed 
CAP.  Interesting is that between values of 0 - 4nglml, two of the seven patients had 
histologically confirmed CaP. Chi square test showed a significant correlation between PSA and 
histology (P= 0.000).  When PSA was cross tested with Gleason score, there was no statistically 
significant relationship    (P= 0.106) .Figure iii shows the relationship between PSA and 
histology. PSA had PPV of 64.9% while the NPV was 96.33%.  
 























































   
Of the Ninety One Patients who had histologically confirmed CAP, and who's  Gleason scores 
were recorded, 17 (18.68%) had well differentiated tumors, 33 (36.26%) had moderately well 
differentiated tumors while the remaining 41 (41.06) had poorly differentiated tumors.   When 
Gleason score was tested against histology, there was a statistically significant correlation (P= 
0.000).  Between Gleason score and PSA, there was statistically significant  relationship (P= 
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0.002).  This was different for age and histology (P= 0.431). 
 
Discussion 
Prostate cancer is the leading non cutaneous cancer in the United States of America with a 
disease related death reaching 29,720 in 2013.11  The highest prostate cancer incidence and 
mortality rates are reported in black African American men (AAM) living in the United States.12 
This is exceeded only by Jamaica with an incidence of 304/100,00013. Data available also 
indicate that the peak age for prostate cancer is a decade earlier in black African American men 
in the United States. In this study, the peak decade was 61-70 year group. 
 
Little is known of the disease in Sub Saharan Africa, the poorest Countries of the world14 and the 
origin of the black African American men. Available data are mostly from GLOBOCAN and are 
often unreliable because they are derived mostly from registries covering hospitals, small sub 
national areas or only major cities.15 Apart from the paucity of data in this region, late 
presentation in the advanced stage of the disease implies that the mortality rate may be higher 
than in the AAM currently.16 
 
The introduction of screening programs in the developed world revolutionized the management 
of prostate cancer. This was aimed at early diagnosis at a stage the disease is curable.17 
Currently, in these fortunate areas, concern now centers on issues of over diagnosis and over 
treatment.18 Such screening programs are presently either erratic or unavailable in centers like 
where this study was done and in shot, most of Sub Saharan Africa. Several reasons such as lack 
of awareness, ethical implication of diagnosis and lack of resources have been documented as 
responsible for this 19.  These factors are remarkably at play in this centre with significant 
influence on the outcome of this study. 
 
The two most commonly used variables for screening for prostate cancer are digital rectal 
examination (DRE) and prostate specific antigen (PSA). DRE is the oldest and least invasive 
method though a few patients are averse to it. DRE findings are considered as abnormal when 
the prostate is enlarged, the median groove is obliterated, the lobes are asymmetrical, there are 
(is) suspicious nodules, the seminal vesicles are palpable or the prostate is hard and or 
nodular.20 The positive predictive value (PPV) and the negative predictive (NPV) values of DRE 
of 96.15% and 93.5% in this study, seemingly quite high, are explained by the extremely late 
presentation21 by this rural dwellers. Factors such as poor health care regulation, the claim by 
complementary and alternative medicine (CAM) practitioners in the state media of their ability 
to cure several diseases, poverty and ignorance account for this late presentation22. In this late 
stage of presentation, even the Urology registrar is able to predict prostate cancer based on DRE 
alone. 
 
Prostate specific antigen (PSA) was introduced into clinical practice in the 1986s for the 
purpose of prostate cancer screening.23 Since then, the percentage of patients who present with 
late disease has reduced remarkably in developed communities24.  Percentage free PSA is most 
useful and helpful in deciding on biopsy though in our centre, this decision is usually based on 
total PSA, the upper limit being 4ng/ml. This upper limit has been considered imperfect as 
according to Thomson et al25 at this upper limit, significant number of cancers at lower PSA are 
missed. In our study, of the seven patients with PSA of 4ng/ml and below, who had prostate 
biopsy done based on DRE finding, two (28.57%) were positive for prostate cancer indicating 
that this upper limit may be too high for this community. However, local factors such as the 
source of the kit, storage facilities and efficiency of the laboratories may affect the PSA value 16. 
 
Studies have shown higher PSA values in AAM than CAM 26. However, some studies have 
pointed to factors such as large tumor burden, presence of undetected metastasis rather than 
more aggressive tumor biology, as a cause. Ikwuerowo et al3 in their study indicated that the 
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common association of prostatitis may be responsible for the higher PSA in our environment. 
The overall positive predictive value of PSA above the cutoff of 4ng/ml falls within the often 
documented. In the work of several authors27,28,29  above the cutoff of 4ng/ml, the PPV was 30% 
while at the cutoff of greater than 10ng/ml, PPV was 42-60%. The prostate cancer prevention 
trial which biopsied men with normal PSA levels estimated NPV of 85% for PSA value < 4ng/ml, 
a figure fairly lower than the 96.3% obtained in this study. This is still explainable by the late 
patient presentation with higher PSA values. For instance, patients who presented with PSA 
value of >100ng/ml were all positive for prostate cancer on biopsy. This may mean that in our 
low resource environment, such patients could be spared prostate biopsy and diagnosis based 
on PSA if other features are present.  
 
This study was hospital based, assessing the value of DRE and PSA as tools for screening for 
prostate cancer in patients who already have lower urinary tract symptoms. This to a large 
extent, may have influenced their remarkable performance as screening tools as most of the 
patents presented in the advanced stage. There is a need for community based studies in these 
rural areas to assess these variables and establish community based predictive values in 
preparation for properly regulated screening programs in sub Saharan African countries. This 
will help to avoid unnecessary prostate biopsies 
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